Fig 1: Co-expression of B7-H3 and EGFR in solid tumors.a, b Analysis of B7-H3 and EGFR RNA expression across (a) different cancer types and (b) all cancers using the TCGA dataset. c Flow cytometry analysis of B7-H3 and EGFR protein expressions in various cancer cell lines (n = 44 cell lines). Number on axes represent MFI fold vs. IgG control. d Representative immunohistochemical (IHC) staining of B7-H3 and EGFR in LUSC cancer (n = 75 patients) and normal tissues (n = 3). Staining intensity: +++ (strong); ++ (medium); + (low); - (negative). Scale bar =50 µm. e Linear regression plot of B7-H3 and EGFR H-Score in LUSC (n = 75 patients). f Co-expression of B7-H3 (red) and EGFR (green) on the same cancer cell of LUSC by multiplex immunofluorescence (n = 75 patients). Source data are provided as a Source Data file.
Fig 2: 20G5/Zalu bsAb EGFR signaling inhibition.a Screening workflow schematic. *7B6 binding affinity was below the detection limit. b In vitro efficacy and safety validation. Efficacy: IC50 ratio of monovalent EGFR mAb over B7-H3/EGFR bsAb in PC9-B7-H3 cells. Safety: IC50 ratio of B7-H3/EGFR bsAb in A431 skin cells vs PC9-B7-H3. The IC50 values for B7-H3/EGFR bsAb are the means from three biological replicates. c Growth inhibition assays of NCI-H358 and A431 cell lines (n = 3 biological replicates). d Competitive EGFR binding assay. NCI-H358 cells pre-incubated with fluorescently labeled Zalutumumab (Zalu) were treated with 20G5/Zalu bsAb or Zalu (n = 3 biological replicates). e EGF receptor occupancy assay. Cells treated with 20G5/Zalu or Zalu were stained with AF647-Zalu to quantify unoccupied EGFR (n = 3 biological replicates). f EGFR internalization. Cells were treated with 5 nM IBI334, Zalu, or Null/Zalu and surface EGFR levels were detected using a non-competing anti-EGFR antibody (n = 3 biological replicates). g Western blot of EGFR pathway-related proteins in NCI-H358 cells treated with 20G5/Zalu, Zalu, Null/Zalu or combo (20G5/null + Null/Zalu) (n = 2 biological replicates). h Time-course analysis of EGFR signaling inhibition by Western blot (left, n = 2 biological replicates), and quantitated band intensities (left). i, j Ligand blockade assays. Flow cytometry (left) measuring EGF (i) or TGF-α (j) binding after treatment (n = 3 biological replicates). EGFR signaling pathway was analyzed by Western blot (right, n = 2 biological replicates). k–m Cis-inhibition experiment. Cells were seeded at low-density (3 × 10⁵ cells/10 cm²) to prevent cell-cell contact. l Western blots of WT SK-MES-1 vs B7-H3-overexpressing (B7-H3OE) SK-MES1 treated with indicated antibodies for 4 h (n = 2 biological replicates). (m) Western blot of SK-MES-1 B7-H3OE cells (n = 2 biological replicates). n Cis- vs trans-inhibition. Fluorescence microscopy of pEGFR (red) in SK-MES-1 (white arrows) and GFP + SK-MES-1-B7-H3OE (green) co-cultures with/without 1 nM 20G5/Zalu (n = 3 biological replicates). Schematic (left) and representative images (right) are shown. For EGFR internalization (f), statistical significance was assessed by two-way ANOVA (Tukey’s post hoc test). Data bars are mean ± SD. Source data are provided as a Source Data file.
Fig 3: Structural and mechanistic analysis of the enhanced EGFR signaling suppression by 20G5/Zalu.a Sequence alignment of the B7-H3 domain (IgC) from human (Uniprot ID: Q5ZPR3), cynomolgus monkey (Uniprot ID: A0A7N9CYV2), and mouse (Uniprot ID: Q8VE98). Human 2Ig-B7-H3 (IgC) and human 4Ig-B7-H3 (IgC2) are identical sequences. b Identification of key residue(s) on B7-H3 contributing to 20G5 binding. ExpiCHO cells transiently transfected with plasmids encoding B7-H3-GFP fusions with or without mutations in IgC domain (Q179K, Q199R, M159N, or D160T) were analyzed by flow cytometry to confirm proper expressions (left); Cell binding of 20G5 to B7-H3 mutant-transfected cells is shown (right, n = 2 biological replicates). c–e Epitope mapping of 20G5 to human B7-H3. c Flow cytometry analysis of NCI-H292 cells stably expressing human B7-H3-GFP fusions with mutations Q179K, Q397K, Q179K + Q397K, or no mutation. d 20G5/Zalu to human B7-H3 mutant expressing cells (n = 2 biological replicates). e Growth inhibition of 20G5/Zalu in human B7-H3-mutant expressing NCI-H292 cells (n = 3 biological replicates). f Cryo-electron microscopy (Cryo-EM) map of the 20G5 (Fab’)2 and human B7-H3 complex, segmented by g Cryo-EM map of the 20G5 Fab and B7-H3 (IgC) complex, segmented by chains and contoured at 6 σ, shown in front (left) and side views (right). g A ribbon representation and detailed interactions between 20G5 Fab and B7-H3 (IgC) complex. Residues involved in the interactions between complementarity-determining regions (CDRs) and B7-H3 are depicted as sticks. h Binding of 20G5 mAb to ExpiCHO cells expressing various B7-H3-GFP fusion mutations (n = 3 biological replicates). i Schematic representation of 20G5/Zalu binding to human B7-H3 and inhibition of EGFR activation. Data bar represent mean ± SD. Source data are provided as a Source Data file.
Supplier Page from Sino Biological, Inc. for Human B7-H3 / CD276 (isoform 2) Protein (ECD, His Tag)